EB144: KEI statement on the WHO roadmap on access to medicines, vaccines and health products

Knowledge Ecology International (KEI) delivered the following statement on the WHO roadmap on access to medicines, vaccines and health products (agenda item 5.7.1) on Tuesday evening, 29 January 2019 during the 144th session of WHO’s Executive Board. The WHO Roadmap… Continue Reading

WHO Cancer Report – Key findings

On 18 December 2018, the World Health Organization (WHO) published a “Technical report on Pricing of cancer medicines and its impacts” (hereinafter referred to as the “WHO Cancer Report”). The mandate for the WHO Cancer Report emanates from operative paragraph… Continue Reading

16 groups write open letter to WHO Director-General Dr Tedros: Roadmap on Access to Medicines and Vaccines 2019-2023

UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading

Compensation under 28 USC §1498

More on 1498 here: https://www.keionline.org/cl/28usc1498 There is a discussion of compensation under 28 USC §1498 in Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies. UNDP and World Health Organization. 2005 (pages 18-21 in the UNDP edition, and… Continue Reading

Orphan Drug R&D costs

1997 James Love, Call for More Reliable Costs Data on Clinical Trials, The Marketletter, January 13, 1997. 2017 James Love, Orphan Drugs Designations and Approvals have Something to Say about Risks, Bill of Health, September 25, 2017. James Love, What… Continue Reading

KEI’s opening statement at WIPO’s 2017 General Assembly focuses on role of Chief Economist

This was delivered the afternoon on October 3, 2017.

Opening statement of Knowledge Ecology International – WIPO General Assembly 2017

Thank you, Mr. Vice President.

KEI notes the controversies around the world regarding the costs and benefits of intellectual property policies, including in particular extended terms of copyright protection in some countries, access to copyrighted works out of commerce and in teaching and research, and the role of patents in both promoting and discouraging innovation, and creating barriers to access medicine.

Continue Reading